We focus on the preclinical phase of Alzheimer’s disease, as it offers an opportunity to visualize tau and amyloid-β binding prior to widespread pathology and neuronal death; preclinical Alzheimer’s disease may also be a prime window for intervention. Here, MAPT is linked to Alzheimer disease.